GU Ventures visited Oslo Cancer Cluster Incubator

/in , /by

New connections were made between the incubators in Gothenburg and Oslo.

GU ventures, an incubator that supports projects and companies spawned by the University of Gothenburg, visited Oslo Cancer Cluster on 25-26 January 2023. Anders Waas, Business Development Advisor for GU Ventures, was accompanied by several cancer companies from the Gothenburg milieu, including Sortina Pharma (Sara Rhost and Göran Landberg, Iscaff Pharma (Per Setterberg), Simsen diagnostics (Gustav Johansson) and Oncorena (Börje Haraldsson and Pål Falck).

The OCC Incubator team, consisting of Ketil Widerberg, CEO, Janne Nestvold, COO, and Thomas Andersson, Business Development Advisor, facilitated meetings with several companies from Oslo Cancer Cluster.

GU Ventures also participated at Cancer Crosslinks, an annual educational meeting which gathers prominent experts in oncology, providing a forum for networking and interaction.

Anders Waas commented: “We were very impressed by the research, the start-up companies and the activities at Oslo Cancer Cluster and strive to build a closer collaboration, which can benefit the development of cancer research and growth of cancer companies in the Oslo – Gothenburg region.”

Thomas Andersson commented: “This was a great experience for Oslo Cancer Cluster Incubator. We were very impressed by the quality of the companies from GU Ventures and look forward to collaborating more closely.”

The post GU Ventures visited Oslo Cancer Cluster Incubator first appeared on Oslo Cancer Cluster.

A number of distinguished researchers will present at Cancer Crosslinks 2023

Meet the speakers of Cancer Crosslinks 2023

/in , /by

Join us for a day of educational talks and mingling with colleagues in the oncology community.

Cancer Crosslinks 2023 will take place on 26 January 2023 (starting at 10:30) in Kaare Norum Auditorium at Oslo Cancer Cluster Innovation Park.

International experts

The programme includes international experts sharing the latest advances in cancer precision medicine and immune-oncology.

The title of Cancer Crosslinks 2023 is New dimensions to the hallmarks of cancer: How is the last decade of discoveries advancing our understanding of cancer biology and transforming precision medicine. It is therefore appropriate that the day begins with a talk from the co-author of The Hallmarks of Cancer.

Douglas Hanahan

Douglas Hanahan

Douglas Hanahan, Distinguished Scholar of the Ludwig Institute for Cancer Research (Zurich/New York), Professor of Molecular Oncology, Swiss Institute for Experimental Cancer Research of the Swiss Federal Institute of Technology Lausanne, Switzerland will give a digital talk on The Hallmarks of Cancer: New Dimensions – Integrating Pre-Clinical and Clinical Cancer Trials of Mechanism-Targeted Therapies.

The three seminal publications are freely available via the following links:

  1. Hanahan D. & Weinberg R. A. (January 2000). “The Hallmarks of Cancer”. Cell. 100 (1): 57–70.
  2. Hanahan, D. & Weinberg, R. A. (March 2011). “Hallmarks of Cancer: The Next Generation”. Cell. 144 (5): 646–674.
  3. Hanahan, D. (Jan 2022) “Hallmarks of Cancer: New Dimensions”. Cancer Discov. 2022 Jan; 12 (1): 31–46.
Mariam Jamal-Hanjani

Mariam Jamal-Hanjani

Mariam Jamal-Hanjani, Group Leader, Cancer Metastasis Lab, CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute; Senior Clinical Lecturer and Honorary Consultant in Translational Lung Oncology, UCL Hospital, London, UK will give a talk on The natural history of non-small cell lung cancer evolution in TRACERx.

Nilofer Azad

Nilofer Azad

Nilofer Azad, Co-Director of Cancer Genetics and Epigenetics, Professor of Oncology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA will give a digital talk on Epigenetic (Combination) Therapy – exploiting complex biology to offer novel treatment options for patients with GI cancers.

Alpaslan (Aslan) Tasdogan

Alpaslan (Aslan) Tasdogan

Alpaslan (Aslan) Tasdogan Associate Professor, German Cancer Consortium (DKTK), Institute for Tumor Metabolism, Department of Dermatology, University Hospital Essen, Germany will give a talk on The metabolic regulation of cancer progression.

Thomas Nerreter

Thomas Nerreter

Thomas Nerreter, Junior Group Leader, Chair of Cellular Immunotherapy, Translational CAR-T Research Program, University Hospital and CCC Würzburg, Germany will give a talk on Cellular Therapy for solid and hematological tumors: novel targets and technologies.

Tom Erkers

Tom Erkers

Tom Erkers, Assistant Professor, Karolinska Institute, Stockholm, Sweden will give a talk on Data-driven hallmarks of acute myeloid leukemia: biological, prognostic & therapeutic implications.

Jakob Nikolas Kather

Jakob Nikolas Kather

Jakob Nikolas Kather, Professor of Clinical Artificial Intelligence, Else Kröner Fresenius Center for Digital Health, Technical University Dresden; Germany will give a talk on AI biomarkers in cancer: recent progress and the way to clinical implementation.

Norwegian moderators

Four Norwegian cancer researchers, representing the milieus at Oslo, Bergen and Trondheim, will guide the audience through the programme.

Katarina Puco

Katarina Puco

Katarina Puco, Senior Consultant Oncologist at Oslo University Hospital, Institute of Cancer research & Lovisenberg Diaconal Hospital, Oslo

Anna Pasetto

Anna Pasetto

Anna Pasetto, Associate Professor, Institute of Clinical Medicine, Division of Cancer Medicine, University of Oslo; Director of the Center for Advanced Cell Therapy (ACT) Cancer Clinic, Oslo University Hospital

May-Britt Tessem

May-Britt Tessem

May-Britt Tessem, Associate Professor/Research Scientist, Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU

Eli Sihn Samdal Steinskog

Eli Sihn Samdal Steinskog

Eli Sihn Samdal Steinskog, Consultant Oncologist, Department of Oncology, Haukeland University Hospital, Bergen, Norway

Mingling with colleagues

The educational programme is complemented by an afternoon networking session starting at 16:15 outside the auditorium. Don’t miss this opportunity to make new connections in the oncology community, revisit old acquaintances and engage in stimulating discussions with other health professionals.

One of the hallmarks of Cancer Crosslinks is the lively networking before, in-between and after the talks. Photo: Cameo UB

 

Register here

 

View and download the programme here

 

Visit the Cancer Crosslinks website here

 

Cancer Crosslinks 2023 is kindly sponsored by Bristol-Myers Squibb and Eli Lilly and Company.

 

                         

 

The post Meet the speakers of Cancer Crosslinks 2023 first appeared on Oslo Cancer Cluster.

The gold label is awarded for excellent cluster management.

Gold Label awarded to Oslo Cancer Cluster

/in , /by

Oslo Cancer Cluster has received the Gold Label certificate from the European Cluster Excellence Initiative (ECEI) with an overall score of 94%.

The Gold Label certificate is granted by the European Cluster Excellence Initiative (ECEI) to cluster organisations that receive at least 80% on their cluster management excellence score. It is the highest recognition a European cluster organisation can achieve.

In October 2022, two independent cluster experts performed an assessment of all 31 quality indicators and awarded Oslo Cancer Cluster a score of 94%.

The indicators concern the quality of:

  • the structure of the cluster,
  • governance,
  • financing,
  • strategy,
  • services,
  • and recognition.

The assessment was performed through interviews with two members of staff. The interviews were also substantiated with relevant documentation.

This was the second time Oslo Cancer Cluster was assessed by the ECEI. The cluster received its first gold label with an overall score of 91% in December 2019.

The Gold Label certificate is valid for two years (until the end of 2024).

The post Gold Label awarded to Oslo Cancer Cluster first appeared on Oslo Cancer Cluster.

Establishing of Cancer Mission Hubs

/in , , /by

The European project ECHoS (Establishing of Cancer Mission Hubs: Networks and Synergies) was recommended for funding by the European Commission.

ECHoS (Establishing of Cancer Mission Hubs: Networks and Synergies) aims to support the implementation of the Cancer Mission activities in all member states and associated countries through the establishment and development of Cancer Mission Hubs operating at national, regional and local levels. 

In Norway, a national Cancer Mission Hub has already been set up in a collaborative effort from various actors of the oncology ecosystem. Several members of the hub are active partners in ECHoS, including Oslo Cancer Cluster, the Norwegian Research Council, the Norwegian Cancer Society, Oslo University Hospital and SINTEF. 

 

Funded by the European Union under the Horizon Europe Framework Programme. Grant Agreement Nº: 101104587. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them. 

The post Establishing of Cancer Mission Hubs first appeared on Oslo Cancer Cluster.